The candidate is an MD trained clinical neurologist whose career goal is to investigate the pathophysiologic causes of Alzheimer's disease, with emphasis on studying Amyloid-Beta metabolism in humans. The proposed period of mentored scientific training in the laboratory of Dr. David Holtzman and clinical research training with Dr. John Morris at Washington University will allow the candidate to develop the skills necessary to become an independent investigator. The central hypotheses that will be tested during the proposed project are as follows: 1) Alzheimer's disease is associated with increased synthesis and/or decreased clearance of the amyloid- beta peptide (A?) in humans. 2) The risk factor of increased age is associated with increased synthesis and/or decreased clearance of A? in humans. 3) The risk factor of ApoE4 genotype is associated with decreased clearance of A? in humans. The candidate proposes to test these hypotheses using a recently developed method to measure the synthesis and clearance rate of A? in vivo in humans. Participants from the Washington University Alzheimer's Disease Research Center (ADRC) will be enrolled in the above studies to compare groups of 1) AD versus non-demented controls, 2) older age, middle age, vs. younger age, and 3) ApoE4 positive vs. ApoE4 negative. A detectable change in A? metabolism in humans that is associated with AD may ultimately lead to better diagnostic and therapeutic options.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23AG030946-04
Application #
7877782
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (M1))
Program Officer
Hsiao, John
Project Start
2007-09-01
Project End
2011-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
4
Fiscal Year
2010
Total Cost
$188,680
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Kinnunen, Kirsi M; Cash, David M; Poole, Teresa et al. (2018) Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. Alzheimers Dement 14:43-53
Yoon, Hyejin; Belmonte, Krystal C; Kasten, Tom et al. (2017) Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery. Sci Rep 7:12720
Hölttä, Mikko; Dean, Robert A; Siemers, Eric et al. (2016) A single dose of the ?-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimers Res Ther 8:11
Patterson, Bruce W; Elbert, Donald L; Mawuenyega, Kwasi G et al. (2015) Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 78:439-53
Roberts, Kaleigh Filisa; Elbert, Donald L; Kasten, Tom P et al. (2014) Amyloid-? efflux from the central nervous system into the plasma. Ann Neurol 76:837-44
Wardlaw, Sharon L; Burant, Charles F; Klein, Samuel et al. (2014) Continuous 24-hour leptin, proopiomelanocortin, and amino acid measurements in human cerebrospinal fluid: correlations with plasma leptin, soluble leptin receptor, and amino acid levels. J Clin Endocrinol Metab 99:2540-8
Mawuenyega, Kwasi G; Kasten, Tom; Sigurdson, Wendy et al. (2013) Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics. Anal Biochem 440:56-62
Esparza, Thomas J; Zhao, Hanzhi; Cirrito, John R et al. (2013) Amyloid-? oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73:104-19
Wildsmith, Kristin R; Basak, Jacob M; Patterson, Bruce W et al. (2012) In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One 7:e38013
Portelius, Erik; Zetterberg, Henrik; Dean, Robert A et al. (2012) Amyloid-?(1-15/16) as a marker for ?-secretase inhibition in Alzheimer's disease. J Alzheimers Dis 31:335-41

Showing the most recent 10 out of 22 publications